SEC Filing Analysis: CapsoVision, Inc. (N/A)

Executive Summary

• Trading Significance: Low
• Key Takeaway: Eliyahou Harari and affiliated trusts have reported a collective 9.2% beneficial ownership stake in CapsoVision, Inc., a privately held medical device company. The filing is a Schedule 13G, indicating a passive investment purpose.
• Market Impact: As CapsoVision, Inc. is not a publicly traded entity with a ticker symbol, this filing has no direct or immediate impact on public equity markets. It is a standard disclosure for significant ownership in a privately held SEC-reporting company.

Company Information

Field	Value
Company	CapsoVision, Inc
Ticker Symbol	null
CIK	0001378325
Industry	Electromedical & Electrotherapeutic Apparatus [3845]

Insider Information

Field	Value
Name	Eliyahou Harari
CIK	0001009165
Title/Position	Trustee
Relationship	Beneficial Owner

Transaction Details

This filing is a Schedule 13G, which reports a significant ownership position rather than a specific transaction. The details reflect the total beneficial ownership as of the event date.

Field	Value
Form Type	SCHEDULE 13G
Event Date	2025-07-01
Transaction Code	null
Security Type	Common Stock, par value $0.001 per share
Shares Involved	Not a single transaction
Price Per Share	null
Total Value	null
Shares Owned After	4,306,503 (9.2% of class)
Ownership Type	Indirect (majority held via trusts)

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: There is no publicly traded stock to impact. This filing is a matter of regulatory compliance for a private entity.

Volume & Sentiment

• Expected Volume Impact: None. No public market exists for the shares.
• Sentiment Indicator: Neutral. This is a statement of position, not a new action that would signal a change in sentiment.

Investment Insights

Positive Market Indicators

• A sophisticated party (Eliyahou Harari and associated trusts) holds a substantial, long-term position in the company, suggesting confidence in its private valuation and future prospects.

Risk Factors

• The primary risk for an investor in such a security is extreme illiquidity, as there is no public market for buying or selling shares.
• As a private company, public information and financial transparency are significantly less than that of a publicly-traded company.

Key Takeaways

1. Significant Passive Stake: The Harari family, through various trusts, holds a major 9.2% stake in CapsoVision, Inc.
2. Complex Ownership Structure: Ownership is distributed between Eliyahou Harari directly (84,084 shares) and indirectly through the Harari Family Trust and two Children Remainder Trusts (4,222,419 shares).
3. No Public Market Impact: This filing is informational for a private company and does not affect public investors or markets.

Contextual Analysis

Timing Significance

The filing date of October 14, 2025, follows an event date of July 1, 2025, which triggered the disclosure requirement. This indicates the acquisition of the stake or the event that pushed ownership over the 5% threshold occurred months prior.

Transaction Context

This is not a market transaction. A Schedule 13G is filed by individuals or institutions that acquire more than 5% of a company's stock with passive intent (i.e., not to exert control). The ownership is based on 46,774,067 shares outstanding as of August 11, 2025, per the company's Form 10-Q.

Company Context

CapsoVision, Inc. is a medical device company in the electromedical apparatus sector. As a private, SEC-reporting entity, it likely has debt instruments or specific classes of equity that require it to file with the SEC, despite not being listed on a major exchange.

Risk Assessment

Risk Level: Low (for public market participants)

Risk Factors

• Illiquidity: Shares are not publicly traded, making it extremely difficult to buy or sell a position.
• Information Asymmetry: Publicly available information is limited compared to listed companies.
• Concentration Risk: A significant portion of ownership is held by a small group of related entities.

Market Considerations

• This filing is irrelevant to public market trading strategies.
• It may be of interest to those in the venture capital, private equity, or medical device M&A sectors who track ownership in private companies.

---

IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.

Analysis generated on 2025-10-14 | Data source: SEC EDGAR